Salt Intake and Disability in Neuromyelitis Optica Spectrum Disorder

被引：0
|
作者：
Maljaei, Mohammad Bagher [1 ]
Shaygannejad, Vahid [2 ,3 ]
Askari, Gholamreza [4 ,5 ]
Maracy, Mohammad Reza [6 ]
Mirmosayyeb, Omid [2 ,3 ]
机构：
[1] Isfahan Univ Med Sci, Isfahan Neurosci Res Ctr, Esfahan, Iran
[2] Isfahan Univ Med Sci, Alzahra Hosp, Isfahan Neurosci Res Ctr, Esfahan, Iran
[3] Isfahan Univ Med Sci, Alzahra Hosp, Dept Neurol, Esfahan, Iran
[4] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Food Secur Res Ctr, Esfahan, Iran
[5] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Dept Community Nutr, Esfahan, Iran
[6] Isfahan Univ Med Sci, Dept Epidemiol & Biostat, Esfahan, Iran
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P152
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [31] Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
    Marignier, Romain
    Bennett, Jeffrey L.
    Kim, Ho Jin
    Weinshenker, Brian G.
    Pittock, Sean J.
    Wingerchuk, Dean
    Fujihara, Kazuko
    Paul, Friedemann
    Cutter, Gary R.
    Green, Ari J.
    Aktas, Orhan
    Hartung, Hans-Peter
    Lublin, Fred D.
    Williams, Ian M.
    Drappa, Jorn
    She, Dewei
    Cimbora, Daniel
    Rees, William
    Smith, Michael
    Ratchford, John N.
    Katz, Eliezer
    Cree, Bruce A. C.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):
  • [32] Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability
    Min, Ju-Hong
    Waters, Patrick
    Vincent, Angela
    Cho, Hye-Jin
    Joo, Byung-Euk
    Woo, Sook-Young
    Lee, Soo-Youn
    Shin, Hee-Young
    Lee, Kwang Ho
    Kim, Byoung Joon
    PLOS ONE, 2014, 9 (09):
  • [33] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [34] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [35] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [36] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [37] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798
  • [38] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [39] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [40] A new era for neuromyelitis optica spectrum disorder
    Silbermann, Elizabeth
    Bourdette, Dennis
    LANCET, 2019, 394 (10206): : 1304 - 1305
12345